|

Anti-PD-L1 Monoclonal Antibody Clinical Trials

3 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Envafolimab

Pipeline

Phase 2: 3

Top Sponsors

  • Yuanquan Yang1
  • Second Affiliated Hospital, School of Medicine, Zhejiang University1
  • City of Hope Medical Center1

Indications

  • Cancer3
  • Colon Neoplasm1
  • Lung Non-Small Cell Carcinoma1
  • Stage IIIB Lung Cancer AJCC v81
  • Stage IV Lung Cancer AJCC v81

Other1 trial

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
Phase 2

Goodyear, Arizona1 trial

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

CTCA at Western Regional Medical Center

Phase 2

Columbus, Ohio1 trial

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.